A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease @ Long Island Clinical Research Associates

Brief description of study

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Clinical Study Identifier: s16-01813
ClinicalTrials.gov Identifier: NCT03105128
Principal Investigator: Lev Ginzburg.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.